Pharsight

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5591762	BOEHRINGER INGELHEIM	Benzimidazoles useful as angiotensin-11 antagonists	Jan, 2014 (10 years ago)

Twynsta is owned by Boehringer Ingelheim.

Twynsta contains Amlodipine Besylate; Telmisartan.

Twynsta has a total of 1 drug patent out of which 1 drug patent has expired.

Expired drug patents of Twynsta are:

Twynsta was authorised for market use on 16 October, 2009.

Twynsta is available in tablet;oral dosage forms.

Twynsta can be used as treatment of hypertension.

The generics of Twynsta are possible to be released after 07 January, 2014.

Drug Exclusivity	Drug Exclusivity Expiration
New Combination(NC)	Oct 16, 2012

Market Authorisation Date: 16 October, 2009

Treatment: Treatment of hypertension

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 5MG BASE;40MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET;ORAL	Discontinued
EQ 10MG BASE;40MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET;ORAL	Discontinued
EQ 5MG BASE;80MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET;ORAL	Discontinued
EQ 10MG BASE;80MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET;ORAL	Discontinued

Twynsta patents expiration